Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Analysis of real-world overall survival (rwOS) among patients with third-line or later (3L+) diffuse large B-cell lymphoma (DLBCL) with multiple qualifying index dates treated in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMichael WallingtonKRKaren RepetnyMFMichelle A. Fanale

Discussion

Loading...

Member takes

Overview

Analysis shows 8 months median overall survival in patients with R/R DLBCL receiving third-line therapy, indicating need for new treatment options.

Key Points

  • Assess real-world overall survival (rwOS) among patients with R/R DLBCL receiving third-line therapy in the US. Identify differences in survival based on treatment eligibility and age.
  • Data analyzed from COTA electronic health records for patients with R/R DLBCL who received 3L+ treatment.
  • Survival outcomes evaluated using Kaplan-Meier method with validation of mortality data from health records.
  • Patients' characteristics, including age and cell of origin, documented at first qualifying index.
  • Analysis included patients aged 18 years and older with at least two prior lines of therapy.
  • Total of 476 unique patients with median age of 67 years at first index and median rwOS of 8.0 months reported.
  • Median rwOS varied: 11.4 months from first index LOT, 6.3 months from last qualifying LOT.
  • Patients with GCB and non-GCB DLBCL had median rwOS of 8.1 and 7.3 months respectively.
  • Results highlight overestimation or underestimation of outcomes based on qualifying index date.

Cite This Study

Wallington et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4dehttps://doi.org/10.1182/blood-2025-4511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy2024 · 18 citations
  2. 2Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database2025
  3. 3Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status2025
  4. 4Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic2026
  5. 5Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The <scp>STRIDER</scp> study2024 · 12 citations